With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Ascendis Pharma's TransCon platform shows promise, but challenges with rollout, competition, and execution risks lead to a Hold rating.

Wegovy is now the second medicine approved in the U.S. for a disease that affects millions. Novo Nordisk has several other factors working in its favor, including strong results and a solid pipeline.

A steep decline in Ozempic maker Novo Nordisk’s share price has sent consumer confidence in Denmark to a three-month low.

European stocks fell Thursday as investors weighed ongoing concerns about the artificial-intelligence boom and data showing gains in business activity. The composite purchasing managers' index for the ...

Patients' vision loss, which is rare according to a new study, is also the subject of multiple lawsuits, including two filed ...

GoodRx and Novo Nordisk are partnering to lower costs for Ozempic and Wegovy. Patients can use GoodRx to access ...

Doustdar, a longtime company insider, took up the chief executive role on Aug. 7, a week after Novo Nordisk cut its outlook for the second time this year blaming competition from copycat versions of ...

As Novo Nordisk transitions from the leadership of longtime CEO Lars Fruergaard Jørgensen to newly appointed chief Maziar ...

(CNN)– Patients in the U.S. can now get Ozempic for half the price, if they pay in cash. Novo Nordisk, the maker of the diabetes drug announced Monday, Aug. 19, that U.S. patients can now get a ...

The drug is available as a weight-loss medication under the brand name Wegovy and will now also be sold directly to diabetes ...

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...